Jiangsu Hengrui Medicine Co., Ltd.

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 17/02/2025			5-day change	1st Jan Change
45.26 ^CNY	-0.53%		-0.07%	-1.39%

17/02	Jiangsu Hengrui Medicine's Drug Marketing License Application Accepted by Chinese Regulator	MT
14/02	Hengrui Medicine Gets Approval for Spondyloarthritis Clinical Trials	MT

Chinese Shares Close Mixed Amid Weak Yuan; Mabwell (Shanghai) Bioscience Down 2%

January 08, 2025 at 01:22 pm IST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine's Drug Marketing License Application Accepted by Chinese Regulator	17/02	MT
Hengrui Medicine Gets Approval for Spondyloarthritis Clinical Trials	14/02	MT
Jiangsu Hengrui Medicine Applies for Drug Marketing Authorization for Insulin Injection	24/01	MT
Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials for Two Anti-tumor Drugs	17/01	MT
Jiangsu Hengrui Medicine Gets China Clinical Trial Approval for Anti-Tumor Injection	15/01	MT
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 Mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531	13/01	CI
Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials on Anti-Tumor Drug	13/01	MT
Jiangsu Hengrui Medicine Gets Drug Registration for Cardiovascular Drug	13/01	MT
Chinese Drug Regulator Accepts Hengrui Medicine's Marketing Application for SHR4640 Tablets	10/01	MT
Chinese Shares Close Mixed Amid Weak Yuan; Mabwell (Shanghai) Bioscience Down 2%	08/01	MT
Jiangsu Hengrui Medicine Files for Hong Kong Listing	08/01	MT
Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials for HRS-6768 Injection	06/01	MT
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2024.	03/01	CI
IDEAYA Biosciences, Inc. Enters Exclusive License with Jiangsu Hengrui Pharmaceuticals Co., Ltd. for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors	29/12	CI
Hengrui Medicine Gets Nod to Trial Prostate Cancer Drug	26/12	MT
Hengrui Medicine Subsidiaries Receive Approval for Anti-Tumor Drug Trial	23/12	MT
Jiangsu Hengrui Medicine Gets China Green Light for Bladder Cancer Drug Combo	19/12	MT
Hengrui Medicine's Unit Included In Chinese Drug Administration's Breakthrough Therapy Drug List	17/12	MT
Hengrui Medicine Gets Nod to Trial Lupus Drug	16/12	MT
Jiangsu Hengrui Medicine Gets Clinical trial Approval for Weight Loss Injection	12/12	MT
Jiangsu Hengrui Medicine's Subsidiaries Get Regulatory Nod to Trial Tumor Drug	11/12	MT
Certain A Shares of Dosilicon Co., Ltd. are subject to a Lock-Up Agreement Ending on 10-DEC-2024.	10/12	CI
Urothelial Carcinoma Drug of Hengrui Medicine's Unit Included in China's List of Breakthrough Drugs	06/12	MT
Jiangsu Hengrui Medicine Gets Drug Registration for Anti-cancer Drugs	03/12	MT
Jiangsu Hengrui Medicine Sees Inclusion of 12 Drugs in National Medical Insurance Catalog; Shares Up 3%	29/11	MT

Chart Jiangsu Hengrui Medicine Co., Ltd.

Duration

Period

Chart Jiangsu Hengrui Medicine Co., Ltd.

600276: Dynamic Chart

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Employees

19,611

Sector

Pharmaceuticals

Calendar

21/04/2025 - Q1 2025 Earnings Release (Projected)

More about the company